Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Annette Mendola, PhD and Richard L. Gibson, MD, MPH
Because research on the efficacy of approaches to addiction recovery is inconclusive, clinicians should recommend several, including 12-step approaches.
AMA J Ethics. 2016;18(6):646-655. doi:
10.1001/journalofethics.2016.18.6.sect1-1606.
This article examines conceptual limitations of extant accounts of palliative psychiatry, with a focus on obligations to distinguish among and clearly formulate goals of care.
AMA J Ethics. 2023;25(9):E710-717. doi:
10.1001/amajethics.2023.710.
When a would-be living organ donor wants to accept risk in the name of altruism when there is little chance for benefit or significant chance for harm, physicians are justified in limiting that altruism.
While respecting patient autonomy and involving patients in decision making, physicians must recognize that some situations call for them to exercise selective paternalism in order to fulfill their professional duty to uphold standards of care.